A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 1,001–1,100 of 1,138
Jones, D. E. (2018) · Wiley eBooks · doi:10.1002/9781119237662.ch17 · Cited by 1
Self-citationKommentar zu: Primär biliäre Cholangitis: Elafibranor durchläuft erfolgreich Phase-III-Prüfung
Sebode, M. (2024) · Gastroenterologie up2date · doi:10.1055/a-2410-4314
Advances in treatment options for patients with primary biliary cholangitis
Parés, A. R. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1394840
“OCA 5mg daily, titrated to 10mg daily [55].”
BackgroundInfluence of bile acids metabolism on hepatic immunity in mice
Guinot, V. (2022) · theses.fr (ABES) · doi:10.70675/b69bb11eza30fz4874z9af2za6e31b2d5ad8
(2000) · Time to knit · doi:10.1016/s1155-1976(17)59785-5
Deceased Donor Liver Transplantation: The Pendulum of Visions and Ideas
Lerut, J. P., & Lai, Q. (2022) · Springer eBooks · doi:10.1007/978-981-19-0063-1_64 · Cited by 1
Bresson‐Hadni, S., & Thiéfin, G. (2019) · HEGEL - HEpato-GastroEntérologie Libérale · doi:10.3917/heg.094.0355
Stratified medicine and primary biliary cholangitis
Mells, G. F., & Jones, D. E. J. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30047-x
Self-citationTakeuchi, A., Komori, A., Kawata, K., Yoshida, O., Tanaka, A., Abe, K., Fujinaga, Y., Namisaki, T., Kimura, N., Katsumi, T., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70246
Bile acid-based therapeutics: recent advances in bile acid conjugates and derivatives
Seo, M., Lee, J.-H., Yang, S.-B., Ma, G., Lee, H., Han, J., Ryu, Y., & Park, J. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00830-5
Editorial: Beyond the Withdrawal—Why the POISE Long‐Term Data Still Matter
Carbone, M., & van der Meer, A. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70910
Bile acid signaling in health and disease
Fan, Z., He, M., Liang, T., 张必利, Zhao, N., & Li, P. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00603-4
“The prototypical FXR agonist, OCA, initially showed promise in cholestatic diseases by reducing toxic BA burden and improving bile flow [262].”
AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update
Aghemo, A., Calvaruso, V., Carbone, M., Cazzagon, N., Cristoferi, L., D’Amato, D., D’Ambrosio, R., Fianchi, F., Germani, G., Giannini, E. G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.06.019 · Cited by 3
Self-citationHasan, M. N., Wang, H., Luo, W., Du, Y., Xiong, L., Gu, L., & Li, T. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100936 · Cited by 1
Primary biliary cholangitis: From diagnosis to treatment
Guarino, M. (2018) · Annals of Gastroenterology and the Digestive System · doi:10.33582/2637-4501/1001 · Cited by 1
FXR’s double life in bile ducts
Takahashi, S., & Gonzalez, F. J. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01528-6
Editorial: biochemical responses do not tell the whole story in primary biliary cholangitis
Bowlus, C. L., & Levy, C. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15576
Self-citationQasim, B., Kumari, H., Kashif, S. N., Abbas, S. M. I., Hani, O., Salma, O., Sauleh, A., Adnan, F., Ali, M., Raheem, A., et al. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00464-6
Liang, X., Liang, Y., Liu, S., Yu, L., Liang, Y., & Zhou, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789551
Magen-Darm-Mittel und Lebertherapeutika
Lohse, A. W., & Huber, S. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_32
Magen-Darm-Mittel und Lebertherapeutika
Lohse, A. W., & Mössner, J. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_34
Kumar, S., Shamseddine, N., Yang, H., Zhang, S., Chen, J., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0179
Self-citationCoopération oncogénique et effets métaboliques de FGF19 dans le carcinome hépatocellulaire
Bedoya, J. U. (2021) · theses.fr (ABES) · doi:10.70675/d2df913bz04e7z457dzb21dzf6ae23303e0c
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Neue Therapieoptionen bei primär biliärer Cholangitis
Keitel, V., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01730-2
Webb, G. J., & Hirschfield, G. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47874-8.00016-x
Self-citationWu, Q., Gao, L.-Y., Feng, H., Liu, H.-L., Gao, H., Peng, W., & Li, N. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1797381
“Clinical trials clearly demonstrate a significant increase in pruritus incidence during treatment with FXR agonists (e.g., OCA), though the mechanism remains unclear (56).”
Advances in Management Strategies for Primary Biliary Cholangitis
Rojas-Amaris, N., Marenco‐Flores, A., Barba, R., Mendoza, R., Patwardhan, V. R., & Bonder, A. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00700-y
“…trial, the addition of OCA (5–10 mg daily) to UDCA for 12 months resulted in 46–47% of patients meeting the primary composite endpoint defined as ALP reduction < 1.67 times the ULN, a > 15% reduction from baseline, and a normal bilirubin level, com - pared to only 10% in the placebo group [ 26 ].”
InfluentialNew therapies for primary biliary cholangitis
Sohal, A., Alamgir, M., & Kowdley, K. V. (2026) · Hepatology International · doi:10.1007/s12072-026-11088-2
“In the study, 46–47% of patients receiving OCA met the POISE criteria, compared to only 10% of placebo patients [8].”
InfluentialSelf-citationSu, S., Yang, J., Luo, J., Yang, C., Li, C., Liu, X., Guo, G., & Han, Y. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02154-8
“…response was assessed using the POISE criteria (ALP 1.67 × the upper limit of normal [ULN] with a reduction of at least 15% from baseline, and a normal total bilirubin level), which were also applied to evaluate biochemical response at various time points after fenofibrate discontinuing [23].”
InfluentialObeticholic acid treatment of mice to promote fertilization and reproduction
Liang, M., Yang, H., Xu, L., & Cao, L. (2023) · Zygote · doi:10.1017/s0967199423000400
Scheinberg, A. R., & Levy, C. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00384-z
王, 红. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641476
Bile acids in cancer: From metabolism to immunomodulation
Fang, Q., & Schneider, K. M. (2026) · Immunity · doi:10.1016/j.immuni.2026.07.003 · Cited by 3
Primary biliary cholangitis, a rising health burden
Elnaggar, M., Elkhattib, I., Abomhya, A., & Boyer, J. L. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00165 · Cited by 1
PBC: Better Solutions to Beat Feeling Beat
Phaw, N. A., & Jones, D. E. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05552-3
Self-citationGao, Q., cheng, J., Li, P., & Ma, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-7787327/v2
Magen-Darm-Mittel und Lebertherapeutika
Lohse, A. W., & Huber, S. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_31
Romeo, M., Basile, C., Imperatore, A., Mozzi, G., Nardo, F. D., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2026) · Cells · doi:10.3390/cells15141292 · Cited by 2
Manejo de la enfermedad hepática metabólica grasa
Lucena, A., Torrijo, Y. S., & Herrojo, J. A. (2020) · Revista Andaluza de Patología Digestiva · doi:10.37352/2020432.2
Recurrent Autoimmune Liver Disease and its Scientific Significance
Tanaka, A., Leung, P. S. C., & Gershwin, M. E. (2020) · Wiley eBooks · doi:10.1002/9781119532637.ch14
Primär biliäre Cholangitis (PBC)
Halilbasic, E., Munda, P., & Trauner, M. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23847-5.00052-1
Self-citationCholestatic Immune-Mediated Diseases Management – Part 1
Mandea, M., & Gheorghe, L. S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016072
Levy, C., Carrion, A. F., & Mayo, M. J. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch21 · Cited by 2
Ooi, Q. X., Brendel, K., van Beek, S. W., Zdovc, J. A., Bardol, M., & Dehez, M. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70247 · Cited by 1
Hakim, A., Patwardhan, V. R., & Bonder, A. (2020) · Clinical Liver Disease · doi:10.1002/cld.964
Cholestatic Immune-Mediated Diseases Management – Part 2
Mandea, M., & Gheorghe, L. S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016073
Verbesserte Prognose, aber limitierte Therapieoptionen für PBC und PSC
Koenen, M. T., Zimmermann, H. W., & Trautwein, C. (2019) · Gastro-News · doi:10.1007/s15036-019-0633-1
Magen-Darm-Mittel und Lebertherapeutika
Mössner, J. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_33 · Cited by 3
Dunn, S., Evans, L., Kennedy, C., Wafer, R., Moody, S., Wolstenhulme, F., Burton, E., Konkoth, A. B., Fisher, H., Chadwick, T., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-113812
“As noted in, Clinical effectiveness of Obeticholic Acid (section 4.4) of the NICE guideline for OCA in PBC 19 and based on the findings of the POISE Trial, 20 clinical effectiveness of OCA would be better measured at 10 mg.”
InfluentialSelf-citationSystemischer Pruritus: hämatologische, nephrogene und hepatobiliäre Ursachen im Fokus
Koschmieder, S., Brand, M., & Kremer, A. E. (2026) · Die Dermatologie · doi:10.1007/s00105-026-05722-1
“Für Obeticholsäure ist dies klinisch am besten dokumentiert;inderPOISE-StudietratPru-ritus dosisabhängig häufiger auf als unter Placebo [35].”
American Association for the Study of Liver Diseases, & EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (2026) · Hepatology · doi:10.1097/hep.0000000000001791
Primary Biliary Cholangitis: The Evolving Therapeutic Landscape
Schonfeld, E. A., & Kumar, S. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00741-x
Bolis, F., & Carbone, M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.003
Mayo, M. J. (2022) · Wiley eBooks · doi:10.1002/9781119600206.ch92
Pediatric cirrhosis: special consideration for its diagnosis and management
Costaguta, G. A., & Álvarez, F. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.1005104
10.1016/b978-84-9113-949-2.00091-3
(2000) · Time to knit · doi:10.1016/b978-84-9113-949-2.00091-3
Old and novel prognostic biomarkers in primary biliary cholangitis
Mulinacci, G., Palermo, A., Invernizzi, P., & Carbone, M. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1927700
“Indeed, they identified two years after the introduction of UDCA treatment begin as a better performing outcome, since 54% of patients continued to have decreased ALP levels into the second year of UDCA treatment before reaching a plateau.”
BackgroundInfluentialSelf-citationPrimary Biliary Cholangitis: Autoimmune Hepatitis Overlap Syndrome
Cazzagon, N., & Chazouillères, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_24
Syed, H., Sun, N., Waly, D., Verma, V. M., Smith, M., Shapiro, D. A., Erickson, M., Siminovitch, K. A., Swain, M., Osman, M. S., et al. (2026) · Liver International · doi:10.1111/liv.70764
“First, we developed an ML tool using whole-blood RNA-seq data derived from PBC patients enrolled in the POISE trial, both before and after OCA treatment [6].”
InfluentialSelf-citationHu, Z., Liu, M., Zhu, C., Li, N., Chen, X., Da, B., Li, Y., & Yu, C. (2026) · Inflammation Research · doi:10.1007/s00011-026-02332-4
“Clinical studies have demonstrated that widespread FXR activation disrupts cho - lesterol homeostasis [ 38 ].”
Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis
Zhao, W., Wu, Z., Kou, Q., Qiao, S., Liu, Z., & Zhang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1859342
Response to Low Dose of Obeticholic Acid in Primary Biliary Cholangitis in the Real-World Population
Bona, C., & Lozano, R. (2025) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/6csonlmw3n
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Álvares‐da‐Silva, M. R., Andreoné, P., Arrese, M. A., Corpechot, C., Elbeshbeshy, H. A., Francque, S., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.016 · Cited by 1
Self-citationPatología inflamatoria y autoinmune de la vía biliar
Vallejo‐Senra, N., & Domínguez‐Muñoz, J. E. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.05.021
Immunomodulatory mechanisms of bile acids in autoimmune diseases along the gut-liver axis
Zhang, S., Xiong, X., Wei, S., Meng, R., An, H., & Chen, L. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104183 · Cited by 1
Challenges for diagnosis and treatment of primary biliary cholangitis
Tanaka, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85389-7.00007-7
Schattenberg, J. M. (2020) · Gut · doi:10.1136/gutjnl-2019-320355
Khakoo, N. S., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00039-4
Seladelpar As a PPAR-δ Agonist in PBC: Pharmacological Insights and Clinical Applications
Lourdu, V., & Gayatri Devi, S. (2026) · Oriental Journal Of Chemistry · doi:10.13005/ojc/420108
Magen/Darm- und Lebererkrankungen
Lohse, A. W., & Huber, S. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_12
Sanai, F. M., Alghamdi, A. S., Khathlan, A. A., Qutub, A. A., Quraishi, H. A., Alghamdi, M., ALZaabi, M. E. H., Mawardi, M., Altarrah, M. Y., Alnahdi, N., et al. (2026) · Cureus · doi:10.7759/cureus.113526
Regulation of Immune Cell Functions by Bile Acid-Activated ReceptorsPreprint
Cheung, K. C. P., Jiao, M. A., Loiola, R. A., Chen, X., & Jia, W. P. (2022) · doi:10.22541/au.166899605.52123374/v1
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
Can we cure primary biliary cholangitis?
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102786
Self-citationUrsodeoxycholsäure plus Bezafibrat bei PBC
Rashidi‐Alavijeh, J., & Wedemeyer, H. H. (2018) · Gastro-News · doi:10.1007/s15036-018-0441-z
Shamseddine, N., Yang, H., Zhang, S., Ye, D., Seshasayee, S. M., Chen, J., Kumar, S. R., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0172
“%) proportion of patients who receive UDCA are unable to tolerate the treatment [19–21] .”
Self-citationModern Therapeutic Approaches to the Treatment of Alcoholic Hepatitis
Usanova, A. A., Kuzma, F., Novikova, E. K., & Петровна, С. Н. (2024) · Актуальные проблемы медицины · doi:10.52575/2687-0940-2024-47-2-158-170 · Cited by 1
Wu, C., Cheng, D., Mo, J., et al. (2025) · Mammalian Genome · doi:10.1007/s00335-025-10146-8
Johnson, E. E., Orozco-Leal, G., Al-Assaf, A. S., Wu, H., Agbeleye, O., Hosseini-Jebeli, S., Sotire, T., Dobson, E., Wallace, S. A., Pearson, F., et al. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01525-9
“Indeed, in the 2016 NICE submission for OCA (TA443) and the associated POISE trial [19, 24], the primary endpoint was the same as in the ELATIVE trial.”
Eaton, J. E. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197679753.003.0031
Ruolo dei farmaci non antidiabete nel trattamento della NAFLD
Maurizio Russello, M. L. A. (2021) · il Diabete · doi:10.30682/ildia2102c
Obeticholic acid for the treatment of hepatobiliary disorders
Александровна, П. В., Karelina, E. A., & Okovityi, S. V. (2025) · Новые Санкт-Петербургские врачебные ведомости. · doi:10.24884/1609-2201-2024-103-3-50-55
Ganesh, T., subramani, V., kannan.S, R., & Yuvaraj.G (2026) · Research Square · doi:10.21203/rs.3.rs-8607418/v1
Die erste deutschsprachige Leitlinie zu autoimmunen Lebererkrankungen
Schramm, C., & Strassburg, C. P. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-112776
“[7] Nevens F, Andreone P, Mazzella G et al.”
BackgroundOrthotopic Liver Transplantation: Indications and Contraindications
Lai, Q., Iesari, S., & Lerut, J. P. (2014) · Springer eBooks · doi:10.1007/978-3-319-05543-5_40-1
Lu, Y., lu, S. H. ̆., Chen, C., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202502975
Nouvelles pistes thérapeutiques pour le traitement de la cholangite biliaire primitive
Brice, C., & Louvet, A. (2025) · médecine/sciences · doi:10.1051/medsci/2025109
Cirrhosis and Autoimmune Liver Disease
Stirnimann, G., Ebadi, M., Mason, A. L., & Montaño‐Loza, A. J. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00449-1
Fricke, U., Hein, L., & Schwabe, U. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_3
Reply to: “Seladelpar in patients with primary biliary cholangitis: Need for a closer look!”
Bowlus, C. L., Levy, C., & Hirschfield, G. M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.024
Self-citationBidault, V., Merlen, G., Glénisson, M., Doignon, I., Garcin, I., Pean, N., Boisgard, R., Bedoya, J. U., Sérino, M., Ullmer, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.18.954255
Epidemiology, Pathogenesis and Treatment Progress of Primary Biliary Cholangitis
余, 兴. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153599
Roles and mechanistic insights into bile acids in sepsis pathogenesis
Bao, Y., Zhao, X., An, Z., & Tang, C. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102051
(2000) · Time to knit · doi:10.1016/s1155-1976(19)80145-6
Dichter, J. (2026) · The FASEB Journal · doi:10.1096/fj.202602616rr
Zou, J., Kan, Y., Song, W., Song, S., Huang, D., Liu, J., & Guo, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1847544
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.